Research & Development2019-01-30T19:00:23+00:00

Home About Research & Development

Total R&D Commitment to Enhance Technology Focused on Promotion of Health

Genetic Engineering Technology

Having introduced genetic engineering technology, Denka Seiken became the first commercial producer in Japan of Norovirus (NV) antibodies, and developed diagnostic tests.

Expertise in immunoassays

Denka Seiken is a pioneer in the development of latex-enhanced turbidimetric immunoassays based on the antigen-antibody reaction. The 1st latex-enhanced turbidimetric immunoassay was released in the 1980’.

Monoclonal Antibody Development

Denka Seiken develops and produces various kinds of monoclonal antibodies in-house for viruses, bacteria and plasma proteins. Such monoclonal antibodies are used for various diagnostic reagents.

Sterile Pharmaceutical Manufacturing

In the development and production of vaccines, sterile pharmaceutical manufacturing technology is needed in order to meet the very strict standards. After more than half a century of developing and producing vaccines, Denka Seiken uses advanced sterile handling technology built on its abundant experience, and produces excellent quality vaccines.

Expertise in Cell Culture

Since its foundation, Denka Seiken has established technologies for the culture of numerous bacteria, viruses, and other microorganisms, as well as tissues. We have made the maximum use of our advanced technologies in the development of vaccines and diagnostic reagents.

ABOUT

A History of Innovation and Manufacturing Excellence
Denka Seiken Co., Ltd. is a publicly traded biomedical company founded in 1950 with its head office in Tokyo and manufacturing facilities in Niigata, Japan.

Read More

Sustained and Growing Global Demand for Denka Seiken Products.
Denka Seiken Co., Ltd. is a publicly traded biomedical company founded in 1950 with its head office in Tokyo and manufacturing facilities in Niigata, Japan.

Read More

Total R&D Commitment to Enhance Technology Focused on Promotion of Health
Having introduced genetic modification technology, Denka Seiken became the first commercial producer in Japan of Norovirus(NV) antibodies, and developed in vitro diagnostic tests.

Read More

Ensuring Quality, Safety, Reliability and Effectiveness For All Our Products.
Denka Seiken is determined to make a positive contribution to society as a manufacturer and supplier of a broad range of vaccines and invitro diagnostic test reagents.

Read More

Denka Seiken Co., Ltd.

Head Office:
Nihonbashi Mitsui Tower
1-1 Nihonbashi-Muromachi 2-chome,
Chuo-ku, Tokyo 103-8338, JAPAN

Established:
February 11, 1950

Paid-in Capital:
1,000 million YEN(JP)

Number of Employees:
725 (As of April 1, 2017)

Business:
Production, sales and import and export of clinical chemistry, immunochemistry, bacteriological and virological diagnostic reagents and food/environment testing reagent

Fiscal year ends:
March

Offices:
Factories:
Niigata Plant, Kagamida Plant (Gosen-shi, Niigata)

Branch Offices:
Tokyo, Osaka, Kanetsu

Sales Offices:
Sapporo, Sendai, Nagoya, Hiroshima, Fukuoka

Subsidiaries:
Denka Seiken UK Limited
Denka Seiken USA Incorporated
Denka Seiken (SHANGHAI) Co.,Ltd.